Nexus Pharmaceuticals received U.S. Food and Drug Administration approval for the company’s New Drug Application for Emerphed, the first premixed ephedrine in a ready-to-use 50 mg/10 mL vial.

The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.

Memory-Loss Man Case ‘Like Nothing We Have Ever Seen Before’ •University of Leicester psychologist describes unique case as new to science •38-year-old fit and healthy man suffered memory loss after local anaesthetic and root-canal treatment at dentist •For the past decade he can only remember up to 90 minutes •And he awakes each day thinking […]